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Abstract
Cardiovascular disease (CVD) is a major cause of death in systemic lupus erythematosus (SLE) patients. Although the risk for
cardiovascular events in patients with SLE is significant, the absolute number of events per year in any given cohort remains
small. Thus, CVD risks stratification in patients with SLE focuses on surrogate markers for atherosclerosis at an early stage,
such as reduced elasticity of arteries. Our study was designed to determine whether arterial stiffness is increased in SLE
patients at low risk for CVD and analyze the role for traditional and non-traditional CVD risk factors on arterial stiffness in
SLE. Carotid-femoral pulse wave velocity (PWV) was prospectively assessed as a measure of arterial stiffness in 41 SLE
patients and 35 controls (CTL). Adjustment on age or Framingham score was performed using a logistic regression model.
Factors associated with PWV were identified separately in SLE patients and in controls using Pearson’s correlation coefficient
for univariate analysis and multiple linear regression for multivariate analysis. SLE patients and controls displayed a low 10-
year risk for CVD according to Framingham score (1.863.6% in SLE vs 1.662.8% in CTL, p = 0.46). Pulse wave velocity was,
however, higher in SLE patients (7.161.6 m/s) as compared to controls (6.360.8 m/s; p = 0.01, after Framingham score
adjustment) and correlated with internal carotid wall thickness (p = 0.0017). In multivariable analysis, only systolic blood
pressure (p = 0.0005) and cumulative dose of glucocorticoids (p = 0.01) were associated with PWV in SLE patients.
Interestingly, the link between systolic blood pressure (SBP) and arterial stiffness was also confirmed in SLE patients with
normal systolic blood pressure. In conclusion, arterial stiffness is increased in SLE patients despite a low risk for CVD
according to Framingham score and is associated with systolic blood pressure and glucocorticoid therapy.
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Introduction
Accelerated atherosclerosis accounts for premature mortality
among systemic lupus erythematosus (SLE) patients. Most
specialists now consider SLE as an independent risk factor for
the development of cardiovascular disease (CVD) [1–9].
Although the risk for cardiovascular events in patients with SLE
is significant, the absolute number of events per year in any given
cohort remains small. Thus, CVD risks stratification in patients
with SLE focuses on biological or imaging surrogate markers of
subclinical atherosclerosis in attempt to identify atherosclerosis at
the earliest stage.
Arterial stiffness reflects changes in mechanical wall properties
that occur early at onset of vascular disease and predispose to
major cardiovascular disease. Besides peripheral pulse pressure
(computed as the difference between systolic and diastolic blood
pressure), arterial stiffness is commonly assessed with aortic pulse
wave velocity (PWV) measurement [10]. Factors associated with
increased PWV include age and long-term effects of traditional
cardiovascular risk factors such as blood pressure. In addition,
most studies indicate a predictive value of PWV for cardiovascular
events and mortality, that is additive to traditional risk factors [11].
Arterial stiffness may be a reliable surrogate marker of cardiovas-
cular risk in patients with SLE [12,13].
To date, two major studies have evaluated arterial stiffness in
SLE patients. The first study concluded that PWV was related to
both SLE-related and traditional cardiovascular risk factors. This
study however lacked a control population [14]. The second study
included SLE or rheumatoid arthritis (RA) patients that were
analyzed as a whole [15]. More recently, 2 studies have shown an
PLOS ONE | www.plosone.org 1 April 2014 | Volume 9 | Issue 4 | e94511
association between PWV and metabolic syndrome (MetS) in SLE
patients [16,17]. Our study was designed to determine whether
carotid-femoral PWV as a measure of arterial stiffness is increased
in SLE patients asymptomatic for cardiovascular disease and at
low risk for CVD, in comparison to healthy controls and to
determine the role for traditional and non-traditional CVD risk
factors on arterial stiffness in SLE.
Patients and Methods
Study participants
Forty-one consecutive patients with systemic lupus erythemato-
sus (SLE) followed in the department of Internal Medicine, Bichat
Hospital, Paris-Diderot University, Paris were enrolled between
February and October 2012. All subjects fulfilled at least four of
the American College of Rheumatology criteria for SLE [18]. At
enrolment, patients were treated with prednisone at a stable dose
for at least 3 months. Exclusion criteria consisted of known
coronary disease or symptoms suggestive of CVD (angina,
arrhythmia, congestive heart failure, stroke, and peripheral arterial
disease).
Controls were healthy non-carrier relatives of pseudohypoal-
dosteronism type 1 patients from a clinical study that aimed to
evaluate cardiovascular disease with similar tools (Assistance
Publique-Hoˆpitaux de Paris, NCT00646828). All controls had
undergone vascular ultrasound imaging between 2008 and 2011
and none had coronary disease or symptoms suggestive of CVD.
The first patient with SLE was considered with respect to age and
sex. The clinical trial database was examined to find the first
control patient of the same age 63 years and sex. Matches within
the range were found for 35 SLE participants.
Extensive screening for conventional cardiovascular risk factors
(age, sex, smoking status, family history of coronary artery disease,
body-mass index, waist circumference, hypertension, diabetes
mellitus, Framingham score for 10-year risk of heart attack) was
undertaken in all cases.
SLE-related data were also analyzed: nephritis, thrombosis,
central nervous system involvement, Raynaud’s phenomenon,
cardiac valvulopathy, pulmonary hypertension and medication
including hormonal contraception, statins, hydroxychloroquine,
steroid and immunosuppressive treatment.
A family history of coronary artery disease was defined when a
first-degree relative had suffered a myocardial infarction or stroke
before the age of 55 years in males or before the age of 65 years in
females [19]. Height and weight were measured, and the body-
mass index was calculated as the weight in kilograms divided by
the square of the height in meters. Subjects were considered to
have hypertension if they repeatedly had a systolic blood pressure
(SBP) of at least 140 mm Hg or a diastolic blood pressure of at
least 90 mm Hg. Diabetes mellitus was defined by a persistent
finding of fasting hyperglycemia and the need for antidiabetic drug
therapy [20]. The risk for cardiovascular events was calculated as
the absolute risk within the next 10 years using the Framingham
risk equation, which includes age, sex, total cholesterol level, high-
density lipoprotein cholesterol level, smoking history, and SBP
[19].
Systemic lupus erythematosus disease activity was assessed using
the SELENA-SLEDAI score [21,22].
The diagnosis of antiphospholipid syndrome (APS) was based
on a history of venous and/or arterial thromboses or recurrent
miscarriages in the presence of aPL antibodies in accordance with
published criteria [23].
Blood tests included complete blood count, creatinine, total
cholesterol, high-density lipoprotein cholesterol, low-density lipo-
protein cholesterol, triglycerides, glycated hemoglobin, homocys-
teine, 25(OH)-D3 vitamin, lupus serology (anti-DNA antibodies,
complement) and antiphospholipid antibodies (anticardiolipin and
anti-b2GP1 antibodies, lupus anticoagulant). Urine sample was
assayed for creatinine, red blood cells and proteins.
Vascular assessment
Vascular ultrasound study was performed in the context of care,
in a temperature-controlled room after a 15 min rest (Vivid 7,
General Electric, Horten, Norway). All subjects had fastened for at
least 12 hours before PWV evaluation. A single investigator
conducted vascular measurements in controls and SLE patients.
All data were analysed offline (EchoPAC, General Electric
Ultrasound). Aortic pulse wave velocity (PWV) was measured by
the carotid to femoral method [24]. The time delay between ECG
R wave and the Doppler flow onset was measured at right
common carotid artery and common femoral artery and the
difference was computed (t). D is the body surface distance
between the 2 measurement points minus the distance from the
suprasternal notch to the carotid measurement point. PWV was
computed as D/t. Internal carotid wall thickness (ICWT) was
measured at the carotid bulb level at end diastole, as gated on
ECG. Right and left values were averaged for each patient.
Carotid plaques were defined as thickness greater than 2 mm.
Statistical analysis
Continuous variables are expressed as mean (SD) or median
(IQR). Categorical variables are expressed as frequencies and
percentages. Data were compared between SLE patients and
controls using Chi2 test (or Fisher) for dichotomous variables and
Student test (or Wilcoxon non-normally distributed) for continuous
variables. The two-way ANOVA test was performed when
specified. Arterial stiffness was compared between SLE patients
and controls using the Wilcoxon rank-sum test. Adjustment on age
or Framingham score was performed with a logistic regression
model. Factors associated to PWV were identified separately in
SLE patients and in controls by use of the Pearson’s correlation
coefficient (univariate analysis) and multiple linear regression
(multivariate analysis). Variables correlated to PWV in univariate
analysis with a p-value below 10% were considered for the
multivariate model. Variable selection relied on the AIC index.
Ethics statement
Our study is a human non-interventional study where 1-subjects
were not assigned to treatment, 2-subjects were assigned to a
diagnosis strategy within current practice (i.e. vascular ultrasound),
3-study involved products with a marketing authorization that are
prescribed in the usual manner and used in accordance with
French agencies authorizations (i.e. vascular ultrasound), 4-
epidemiological methods were used to analyze the data, and 5-
information used in the study were collected for clinical care.
According to the Public Health French Law (art L 1121-1-1, art
L 1121-1-2), approval from institutional review board and written
consent are not required for human non-interventional studies.
For ethical consideration, patients were however informed that
data that was collected in medical records might be used for
research study in accordance to privacy rule. Written informed
consent was obtained from each patient and the study protocol
conforms to the ethical guidelines of the 1975 Declaration of
Helsinki. Our study involves personal health data and has been
authorized by the Commission nationale de l’informatique et des
liberte´s (CNIL) (declaration number 1685680 v 0)
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Results
Characteristics of SLE patients and controls
Forty-one SLE patients and 35 controls (CTL) were studied.
The mean age of SLE subjects was 39610 years (3768 in controls)
and 34 (82.9%) were female (80% in controls). Forty patients
(97.5%) received long-term glucocorticoids and 27 (65.9%) still
used prednisone at a mean daily dose of 963 mg (range: 5–17) at
study time. Twenty-eight (68.3%) had received immunosuppres-
sive or immunomodulatory drugs at some point during follow-up.
SLE patients were treated with angiotensin converting enzyme
inhibitor or angiotensin receptor antagonist (n = 18), beta blocker
(n = 3) or calcium channel blocker (n = 1). No control subject was
receiving anti-hypertensive drugs at PWV measurement.
Age, sex, tobacco use, hypertension, diabetes, BMI, LDL-
cholesterol level, or absolute risk of cardiovascular events
occurring within the next 10 years according to the Framingham
score were not statistically different between SLE patients and
Table 1. Characteristics of SLE (systemic lupus erythematosus) and controls subjects.
SLE patients (n =41) Controls (n =35) p
Female Sex, n (%) 34 (82.9) 28 (80) 0.77
Age, years 39 (610) (21–62) 37 (68) (23–59) 0.21
Familial History of CAD, n (%) 1 (2.4) NA
Smoker current, n (%) 14 (34.1) 12 (34.3) 1
Hypertension, n (%) 12 (29.2) 8 (22.9) 0.61
Diabetes, n (%) 1 (2.4) 1 (2.8) 1
BMI, kg/m2 25.5 (65.4) (18–44) 26.7 (66.6) (19–41) 0.69
Waist circumference, cm 93.4 (615) (72–150) 94.9 (615.5) (78–131) 0.63
Systolic Blood Pressure, mmHg 130+18 (96–169) 127+11 (115–150) 0.37
LDL-Cholesterol, g/l 0.92 (60.3) (0.36–1.53) 1.2 (60.3) (0.62–1.73) 0.001
HbA1c, % 5.4 (60.5) (4.4–6.7) 5.4 (60.4) (4.7–6.1) 0.39
10-year risk of heart attack, % 1.8 (63.6) (0.5–23) 1.6 (62.8) (0.5–16) 0.53
Homocysteine/creatinine ratio 0.18 (60.07) (0.06–0.42)
25(OH)-D3 vitamin, ng/ml 23.4 (611.5) (5–41.7)
GFR, ml/mn/1.73 m2 84.9 (634.6) (16.3–168.4) 102 (621) (63–164) 0.002
Proteinuria/Creatininuria, mg/mmol 85.4 (6215) (5–1188)
Lymphocytes, G/l 1.4 (60.6) (0.3–3.4)
Duration of SLE disease, y 13 (67.3) (1–37)
SELENA SLEDAI score 2.1 (62.8) (0–13)
Lupus nephritis, n (%) 27 (65.8)
LA antibodies, n (%) 7 (17)
aCL antibodies, n (%) 12 (29.3)
anti-B2GP1 antibodies, n (%) 2 (4.9)
APS, n (%) 5 (12.2)
Cumulative years of steroid treatment 10.5 (67) (0–26)
Cumulative dose of steroid treatment, g 42.3 (629.2) (0–132)
Antiplatelet treatment, n (%) 7 (17.1)
Anticoagulant treatment, n (%) 6 (14.6)
Hormonal contraception, n (%) 12/34 (35.3)
Statin, n (%) 10 (24.4) 1 (2.8) 0.009
Hydroxychloroquine, n (%) 41 (100)
Other therapy, n (%) 28 (68.3)
CAD, coronary artery disease; BMI, body mass index; SELENA, safety of estrogens in lupus erythematosus national assessment; SLEDAI, systemic lupus erythematosus
disease activity index; LA, lupus anticoagulant; aCL, anti-cardiolipin antibody; b2GP1, b2-Glycoprotein 1; APS, antiphospholipid syndrome.
10-year risk of heart attack was calculated using the Framingham equation.
Normal value for homocysteine/creatinine ratio was below 0.17.
Normal value for 25(OH)-D3 vitamin was above 30 ng/ml (nanogram per liter)
GRF, glomerular rate filtration, calculated with the Modification of Diet in Renal Disease (MDRD) equation and expressed in milliliters per minute per 1.73 square meters
of body surface area
Hormonal contraception was progestin-only pill in all cases.
Other therapy included cyclophosphamide (n = 24), azathioprine (n = 14), mycophenolatemofetil (n = 11), methotrexate (n = 3), rituximab (n = 1), or intravenous
immunoglobulin (n = 1)
cm, centimeter; g/l, gram per liter; g, gram; millimeter of mercure, mmHg
Results are shown as mean and (SD), and (range)
doi:10.1371/journal.pone.0094511.t001
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controls. LDL-cholesterol level was lower in SLE patients as
compared to controls (0.9260.3 vs 1.260.3 g/l, p = 0.001). Only
one SLE subject (2.4%) had a family history of CVD.
Among non-traditional CVD risk factors in SLE patients, waist
circumference was above 88 cm (ranging from 90 to 150 cm) in
64.7% (22/34) of women and above 102 cm in 14.3% (1/7) of
men. Sixteen (39%) patients had a blood homocysteine/
creatinine ratio above the normal value of 0.17 (range: 0.18 to
0.42). Twenty-four (61%) had a vitamin D deficiency assessed by
a blood level of 25(OH)-D3 vitamin below 30 ng/ml (range: 5 to
28.1).
Clinical characteristics of SLE patients and controls are shown
in detail in Table 1.
Arterial stiffness and carotid wall thickness are higher in
SLE patients
Pulse wave velocity (PWV) was higher in SLE patients as
compared to controls as shown in Figure 1A (7.161.6 vs
6.360.8 m/s; p= 0.02 after age adjustment; p= 0.01 after
Framingham score adjustment). In the same line, internal carotid
wall thickness (ICWT) was higher in SLE patients (ICWT:
1.3160.67 vs 0.9360.25 mm; p= 0.007 after age adjustment;
p = 0.003 after Framingham score adjustment) and eight (19.5%)
SLE patients, but only one control (2.8%) (p= 0.03), displayed a
carotid atherosclerotic plaque as defined as a local wall thickening
greater than 2 mm. Moreover in SLE patients, PWV significantly
correlated with ICWT (r = 0.63, 95% CI: 0.4–0.79, p = 0.0017
after age adjustement) (Figure 1B).
Risk factors for arterial stiffness: univariate analysis
In SLE patients, PWV was shown to correlate positively with
age, systolic blood pressure (SBP), cumulative dose of glucocor-
ticoids and glomerular filtration rate (GFR). No statistical
relationship was found between PWV and Framingham score,
BMI, blood levels of LDL-cholesterol, homocystein, 25(OH)-D3
vitamin, lymphocytes count, anti-dsDNA antibodies level, current
dose of steroids, C3 level, anti-b2GP1 or anticardiolipine
antibodies levels and SELENA SLEDAI score. Correlations
between PWV and glycated hemoglobin or duration of SLE
disease failed to reach statistical significance (Table 2). In controls,
PWV only correlated with age and Framingham score (Table 3).
The frequency of subjects with high blood pressure (29.2% of
SLE patients vs 22.9% of controls, p = 0.61) and the mean SBP at
study time (130618 in SLE vs 127611 in CTL, p= 0.37) did not
significantly differ between groups. Interestingly, after stratification
according to SBP quartiles, the correlation between SBP and
PWV for a given level of SBP appeared to be higher in SLE
patients as compared to controls. Indeed the interaction between
SBP and SLE status was accounting for 11.7% of the observed
variance (p = 0.002) (Figure 1C). Moreover, the correlation
between PWV and SBP was observed even in SLE patients
without high systolic blood pressure (r = 0.50, p = 0.006)
(Figure 1D).
The proportion of SLE patients with high blood pressure and
the mean SBP at study time did not significantly differ between
patients that were currently receiving or not glucocorticoid (33.3%
(9/27) vs 35.7% (5/14), p = 1.00 and 130617 (range: 96–169) vs
132619 (108–165) mmHg, p= 0.67; respectively).
Figure 1. Pulse Wave Velocity (PWV) is high in SLE patients and correlates with systolic blood pressure. (A) Pulse wave velocity (PWV)
are higher in SLE patients (SLE, n = 41, right) as compared to controls (CTL, n = 35, left) and (B) correlated with internal carotid wall thickness (ICWT).
(C) SLE patients and controls were stratified according to systolic blood pressure quartiles (SBP ,119; 120–126, .127–135, .137 mmHg). Two-ways
ANOVA showed a significant independent interaction of SBP and group (SLE, CTL) on PWV. (D) PWV correlated with systolic blood pressure (SBP) in
SLE subjects with (white circles) and without (black circles) high systolic blood pressure. Plain and dashed lines represented linear regression in SLE
subjects with and without high systolic blood pressure (SBP), respectively. p was calculated after age adjustment. m/s refers to meter per second;
mm, to millimeter; r, to linear correlation coefficient
doi:10.1371/journal.pone.0094511.g001
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Table 2. Univariate analysis of risk factors for arterial stiffness in SLE subjects.
Number of subjects Mean PWV (SD) Median PWV (IQR) p
Sex 0.60
Male 7 4.9 (9.3) 6.8 (1.5)
Female 34 4.7 (12.1) 7.2 (1.6)
Smoker current 0.54
No 27 4.7 (10.1) 7.0 (1.5)
Yes 14 4.9 (12.1) 7.3 (1.9)
Diabetes 0.78
No 40 4.7 (12.1) 7.1 (1.6)
Yes 1 7.5 (7.5) 7.5 (.)
High blood pressure ,0.0001
No 29 4.7 (9.4) 6.4 (1.0)
Yes 12 5.7 (12.1) 8.5 (1.6)
Statin 0.85
No 31 4.7 (12.1) 7.1 (1.5)
Yes 10 4.9 (10.1) 7.0 (1.9)
Lupus Nephritis 0.40
No 14 4.9 (10.1) 6.8 (1.5)
Yes 27 4.7 (12.1) 7.2 (1.7)
Familial History of CAD 0.66
No 40 4.7 (12.1) 7.1 (1.6)
Yes 1 7.8 (7.8) 7.8 (.)
APS 0.54
No 36 4.7 (10.1) 7.0 (1.4)
Yes 5 4.9 (12.1) 8.0 (2.8)
Linear correlation coefficient 95% CI P
Age 0.49 0.21 to 0.69 0.001
Systolic blood pressure 0.67 0.44 to 0.81 ,0.0001
GFR 20.52 20.71 to 20.25 0.0003
BMI 0.13 20.18 to 0.42 0.41
10-year risk of heart attack 0.23 20.08 to 0.5 0.14
LDL-Cholesterol 0.12 20.20 to 0.41 0.47
Waist circumference 0.08 20.24 to 0.38 0.62
HbA1c 0.26 20.05 to 0.52 0.10
Cumulative steroid dose 0.38 0.07 to 0.61 0.01
Homocysteine/creatinine ratio 20.23 20.5 to 0.09 0.16
25(OH)-D3 vitamin 0.03 20.29 to 0.34 0.84
Duration of SLE disease 0.26 20.05 to 0.53 0.10
Proteinuria/Creatininuria 0.15 20.17 to 0.44 0.37
SELENA SLEDAI score 20.18 20.46 to 0.14 0.27
C3 0.24 20.04 to 0.50 0.09
CAD, coronary artery disease; BMI, body mass index; SELENA, safety of estrogens in lupus erythematosus national assessment; SLEDAI, systemic lupus erythematosus
disease activity index; APS, antiphospholipid syndrome.
10-year risk of heart attack was calculated using the Framingham equation.
Normal value for homocysteine/creatinine ratio was below 0.17.
Normal value for 25(OH)-D3 vitamin was above 30 ng/ml (nanogram per liter)
GRF, glomerular rate filtration, calculated with the Modification of Diet in Renal Disease (MDRD) equation and expressed in milliliters per minute per 1.73 square meters
of body surface area
PWV, pulse wave velocity is expressed in meter per second
IQR, interquartile range
SD, standard deviation
doi:10.1371/journal.pone.0094511.t002
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Twenty-seven (65.8%) SLE patients had experienced lupus
nephritis in the past, mostly (20/27, 74%) class IV diffuse nephritis
according to International Society of Nephrology/Renal Pathol-
ogy Society (ISN/RPS) classification of lupus nephritis [25]. No
SLE patient displayed active lupus nephritis at study time. No
history of renal disease was reported in controls. The glomerular
filtration rate (GFR), calculated with the Modification of Diet in
Renal Disease (MDRD) equation, was below 60 ml/mn/1.73 m2
(range: 16.3 to 55.6) in 8 (19.5%) SLE patients. All control subjects
displayed a GFR above 60 ml/mn/1.73 m2 (p = 0.01, as com-
Table 3. Univariate analysis of risk factors for arterial stiffness in Control subjects.
Number of subjects Mean PWV (SD) Median PWV (IQR) p
Sex 0.73
Male 7 5.5 (7.7) 6.4 (0.8)
Female 28 5.0/9.0 6.2 (0.9)
Smoker current 0.51
No 23 5.0/9.0 6.3 (0.8)
Yes 12 5.1/7.7 6.1 (0.8)
Diabetes 0.69
No 1 6.6/6.6 6.6 (.)
Yes 34 5.0/9.0 6.3 (0.8)
High blood pressure 0.33
No 27 5.0/7.7 6.2 (0.7)
Yes 8 5.5/9.0 6.5 (1.1)
Linear correlation coefficient 95% CI p
Age 0.48 0.17 to 0.70 0.003
Systolic blood pressure 0.17 20.17 to 0.48 0.32
GFR 20.15 20.46 to 0.19 0.38
BMI 0.04 20.30 to 0.37 0.82
10-year risk of heart attack 0.37 0.03 to 0.62 0.03
LDL-Cholesterol 0.30 20.04 to 0.57 0.08
Waist circumference 0.04 20.30 to 0.37 0.82
HbA1c 0.05 20.29 to 0.38 0.78
BMI, body mass index;
10-year risk of heart attack was calculated using the Framingham equation
GRF, glomerular rate filtration, calculated with the Modification of Diet in Renal Disease (MDRD) equation and expressed in milliliters per minute per 1.73 square meters
of body surface area
PWV, pulse wave velocity is expressed in meter per second
IQR, interquartile range
SD, standard deviation
doi:10.1371/journal.pone.0094511.t003
Table 4. Multivariate analysis of risk factors for arterial stiffness.
SLE subjects
Linear correlation coefficient Unstandardized betas 95% CI p
Age 0.49 0.03 0.21 to 0.69 0.08
Systolic blood pressure 0.67 0.04 0.44 to 0.81 0.0005
GFR 0.52 20.008 0.71 to 0.25 0.17
Cumulative steroid dose 0.38 0.015 0.07 to 0.61 0.01
Controls
Linear correlation coefficient Unstandardized betas 95% CI p
Age 0.48 0.04 0.17 to 0.70 0.005
LDL-Cholesterol 0.30 0.69 0.04 to 0.57 0.10
GRF, glomerular rate filtration, calculated with the Modification of Diet in Renal Disease (MDRD) equation and expressed in milliliters per minute per 1.73 square meters
of body surface area
doi:10.1371/journal.pone.0094511.t004
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pared to SLE). Moreover, the mean GFR was significantly higher
in controls (102621 ml/mn/1.73 m2) as compared to SLE
patients (84.9634.6, p,0.05), especially as compared to SLE
subjects with history of lupus nephritis (74.5630.6, p,0.005).
The mean protein urinary output, assessed by measuring the
morning urinary protein/creatinine ratio, was 84.5 (6215) mg/
mmol in SLE patients and 13 (31%) patients had a ratio above
30 mg/mmol (range: 41.3 to 1188). No correlation was found
between PWV and urinary protein/creatinine ratio in SLE
patients (p = 0.36).
Risk factors for arterial stiffness: multivariate analysis
In the multivariate analysis (Table 4), both systolic blood
pressure (p = 0.0005) and cumulative prednisone intake (p= 0.01)
were associated with arterial stiffness in SLE patients. The
association between age and PWV failed to reach statistical
significance (p = 0.08). In controls, only age was associated with
PWV (p= 0.005)
Discussion
Cardiovascular diseases (CVD) are a major cause of morbidity
and mortality in systemic lupus erythematosus (SLE) [1–6]. The
pathogenesis of CVD associated with SLE is unknown. Our study
shows that, despite a low cardiovascular risk according to
Framingham score, SLE patients display increased arterial stiffness
as compared to controls. Systolic blood pressure (SBP) and
glucorticoid treatment are the main contributors to this phenom-
enon. Moreover we observe that, in SLE patients, increased
arterial stiffness parallels with subclinical atherosclerosis assessed
by internal carotid wall thickness (ICWT) measurement.
Arterial stiffness is a consequence of arterial wall thickening and
early changes in mechanical properties of the vascular wall.
Previous research has found a strong association between
hypertension and arterial stiffness in general population [26,27].
Moreover, hypertension was shown to be associated with an
increased frequency of cardiovascular events (CVE) in SLE
patients [28]. Interestingly, in our study, SBP correlated with
arterial stiffness even in SLE patients with normal blood pressure.
Moreover, at a given level of SBP, the correlation between systolic
blood pressure and arterial stiffness, was stronger in SLE patients
as compared to controls.
Hypercholesterolemia was reported to be the best predictor of
CVE in SLE patients [28]. We did not confirm such correlation
between hypercholesterolemia and arterial stiffness in SLE
patients. However, treatment with statins was started when the
LDL-cholesterol was.1 g/l according to current guidelines in our
SLE patients [29]. Statin treatment explains the fact that level of
LDL-cholesterol is lower in SLE patients as compared to controls.
In previous studies, SLE-specific variables appeared to be
independently associated with increased PWV [14,17]. Although
we may argue that the cumulative dose of steroid taken is related
to a more severe SLE disease, we do not observe significant
association between SLE-related variables - such as disease activity
score or duration of SLE disease - and arterial stiffness.
Among non-traditional risk factors for atherosclerosis in SLE
patients, the role played by glucocorticoids, a first line treatment
for lupus, remains a matter of debate. The estimated 2-year
coronary risk for a patient treated with an average dosage of
30 mg/day of prednisone for 1 year, is approximately 60% higher
than it would be for a patient with the same SLE activity level and
similar risk factors receiving no steroids [30]. On the other hand,
since inflammation is implicated in atherosclerosis, low dose
corticosteroids may exert a beneficial anti-inflammatory action
[31]. Subclinical atherosclerosis in SLE has indeed been correlated
with both a low dose of corticosteroids and less immunosuppres-
sive drugs [5]. In contrast, our study suggests that, even in subjects
at low risk for CVD according to Framingham score, cumulative
prednisone treatment contributes to arterial stiffness and may play
a role in accelerated atherosclerosis in SLE. An association
between PWV and metabolic syndrome has recently been shown
in two cross-sectional studies in SLE patients [16,17]. Consistent
with our data, metabolic syndrome in SLE patients was also
associated with a higher daily prednisolone dose [32].
Our study has several limitations. First, sample size is small and
our work may lack statistical power to show the effect of SLE-
specific factors on arterial stiffness. Second, causation cannot be
concluded from a cross-sectional study. Eventually, biases cannot
be excluded in the selection of healthy controls.
In conclusion, our results support the fact that both systolic
blood pressure and glucocorticoid therapy are major contributors
to premature arterial stiffness in SLE patients.
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